Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives.
Christian Sávio-SilvaPoliana Evelyn Soinski-SousaMaria Theresa A Balby-RochaÁdyna de Oliveira LiraÉrika Bevillaqua RangelPublished in: Revista da Associacao Medica Brasileira (1992) (2020)
Cellular therapy with MSCs is very promising and should be part of the treatment of AKI patients in combination with other approaches already available, helping to accelerate recovery and/or slow the progression to chronic kidney disease. Randomized, multicentre controlled studies are needed to develop robust protocols that validate population-based cell therapy with MSCs.
Keyphrases
- cell therapy
- acute kidney injury
- mesenchymal stem cells
- end stage renal disease
- chronic kidney disease
- cardiac surgery
- umbilical cord
- peritoneal dialysis
- double blind
- newly diagnosed
- ejection fraction
- stem cells
- clinical trial
- bone marrow
- prognostic factors
- study protocol
- randomized controlled trial
- cross sectional
- patient reported outcomes
- patient reported